Molecular and genetic pathways in gliomas: the future of personalized therapeutics

Papers of special note have been highlighted as:

• of interest

•• of considerable interest

References

• 1 CBTRUS, CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2008. CBTRUS, Hinsdale, IL, USA (2012).
  Google Scholar
• 2 Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL. Epidemiology of brain tumors. Neurol Clin. 25, 867–890 (2007).
  MedlineGoogle Scholar
• 3 Rousseau A, Mokhtari K, Duyckaerts C. The 2007 WHO classification of tumors of the central nervous system – what has changed? Curr. Opin. Neurol. 21, 720–727 (2008).
  MedlineGoogle Scholar
• 4 Fuller GN, Scheithauer BW. The 2007 Revised World Health Organization (WHO) Classification of Tumours of the Central Nervous System: newly codified entities. Brain Pathol. 17, 304–307 (2007).
  MedlineGoogle Scholar
• 5 Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
  Medline CASGoogle Scholar
• 6 Westphal M, Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat. Rev. Neurosci. 12, 495–508 (2011). • Good complimentary review detailing molecular pathways in gliomas and potential therapeutic targets.
  Medline CASGoogle Scholar
• 7 Grossman SA, Ye X, Piantadosi S et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res. 16, 2443–2449 (2010).
  Medline CASGoogle Scholar
• 8 Zhang J, Wu G, Miller CP et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat. Genet. 45, 602–612 (2013). •• Landmark paper identifying multiple new genetic alterations in low-grade gliomas, including BRAF, RAF1, FGFR1, MYB, MYBL1 and genes with histone-related functions, including H3F3A and ATRX.
  Medline CASGoogle Scholar
• 9 van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo. 5, 223–227 (2012).
  MedlineGoogle Scholar
• 10 Turcan S, Rohle D, Goenka A et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479–483 (2012). • IDH1 mutation is responsible for epigenetic methylation.
  Medline CASGoogle Scholar
• 11 Shinawi T, Hill VK, Krex D et al. DNA methylation profiles of long- and short-term glioblastoma survivors. Epigenetics 8, 149–156 (2013).
  Medline CASGoogle Scholar
• 12 Bettegowda C, Agrawal N, Jiao Y et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333, 1453–1455 (2011). • Specific genes mutated in oligodendrogliomas besides the well-known 1p/19q mutation.
  Medline CASGoogle Scholar
• 13 Zhang C, Moore LM, Li X, Yung WK, Zhang W. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol. 15, 1114–1126 (2013).
  Medline CASGoogle Scholar
• 14 Smoll NR, Gautschi OP, Schatlo B, Schaller K, Weber DC. Relative survival of patients with supratentorial low-grade gliomas. Neuro Oncol. 14, 1062–1069 (2012).
  MedlineGoogle Scholar
• 15 Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21, 2683–2710 (2007).
  Medline CASGoogle Scholar
• 16 Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 64, 479–489 (2005).
  Medline CASGoogle Scholar
• 17 Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 14(Suppl. 5), v1–v49 (2012).
  MedlineGoogle Scholar
• 18 Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008). •• Glioblastoma has key mutations in MGMT, TP53, ERB and PI3K pathways.
  Medline CASGoogle Scholar
• 19 Schwartzentruber J, Korshunov A, Liu XY et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226–231 (2012). •• New mutations identified in histone and epigenetic remodeling systems in glioblastoma (GBM). This paper helped pave the way that mutations in GBM go beyond just mutations in the genetic structure and instead stretch into the epigenetic realm.
  Medline CASGoogle Scholar
• 20 Wu G, Broniscer A, McEachron TA et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44, 251–253 (2012).
  Medline CASGoogle Scholar
• 21 Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 170, 1445–1453 (2007).
  Medline CASGoogle Scholar
• 22 Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17, 98–110 (2010).
  Medline CASGoogle Scholar
• 23 Gao Q, Lei T, Ye F. Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma. Expert Opin. Investig. Drugs. 22, 1023–1040 (2013).
  Medline CASGoogle Scholar
• 24 Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J. Clin. Neurosci. 16, 748–754 (2009).
  Medline CASGoogle Scholar
• 25 Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J. Pathol. 207, 224–231 (2005).
  Medline CASGoogle Scholar
• 26 Quayle SN, Lee JY, Cheung LW et al. Somatic mutations of PIK3R1 promote gliomagenesis. PLoS ONE 7, e49466 (2012).
  Medline CASGoogle Scholar
• 27 Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 9, 157–173 (2006).
  Medline CASGoogle Scholar
• 28 McNamara MG, Sahebjam S, Mason WP. Emerging biomarkers in glioblastoma. Cancers (Basel) 5, 1103–1119 (2013).
  Medline CASGoogle Scholar
• 29 Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355, 846–847 (1992).
  Medline CASGoogle Scholar
• 30 Bogler O, Huang HJ, Cavenee WK. Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. Cancer Res. 55, 2746–2751 (1995).
  Medline CASGoogle Scholar
• 31 Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat. Rev. Clin. Oncol. 10, 14–26 (2013). • Discusses additional potential therapeutic targets in glioma.
  Medline CASGoogle Scholar
• 32 Bredel M, Scholtens DM, Yadav AK et al. NFKBIA deletion in glioblastomas. N. Engl. J. Med. 364, 627–637 (2011). • New pathway mutation identifed in GBM allows for constitutively active NF-κB.
  Medline CASGoogle Scholar
• 33 Chowdhary S, Chamberlain M. Bevacizumab for the treatment of glioblastoma. Expert Rev. Neurother. 13, 937–949 (2013).
  Medline CASGoogle Scholar
• 34 Zerbini G, Lorenzi M, Palini A. Tumor angiogenesis. N. Engl. J. Med. 359, 763; author reply 764 (2008).
  Medline CASGoogle Scholar
• 35 Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8, 610–622 (2007).
  Medline CASGoogle Scholar
• 36 Shih Ie M, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res. 67, 1879–1882 (2007).
  MedlineGoogle Scholar
• 37 Jansen M, Yip S, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 9, 717–726 (2010).
  Medline CASGoogle Scholar
• 38 Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005). Landmark paper demonstrating the MGMT gene silencing predicts chemotherapy response.
  Medline CASGoogle Scholar
• 39 Nutt CL. Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology. Neurosurg. Focus. 19, E2 (2005).
  MedlineGoogle Scholar
• 40 Weller M, Gorlia T, Cairncross JG et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77, 1156–1164 (2011).
  Medline CASGoogle Scholar
• 41 Hegi ME, Janzer RC, Lambiv WL et al. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol. 123, 841–852 (2012).
  Medline CASGoogle Scholar
• 42 Wiestler B, Capper D, Holland-Letz T et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 126, 443–451 (2013).
  Medline CASGoogle Scholar
• 43 Hartmann C, Hentschel B, Wick W et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 120, 707–718 (2010).
  MedlineGoogle Scholar
• 44 Sanson M, Marie Y, Paris S et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 27, 4150–4154 (2009).
  Medline CASGoogle Scholar
• 45 Mulholland S, Pearson DM, Hamoudi RA et al. MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. Int. J. Cancer 131, 1104–1113 (2012).
  Medline CASGoogle Scholar
• 46 Horbinski C, Kofler J, Yeaney G et al. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol. 21, 564–574 (2011).
  Medline CASGoogle Scholar
• 47 Patel M, Vogelbaum MA, Barnett GH, Jalali R, Ahluwalia MS. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin. Investig. Drugs. 21, 1247–1266 (2012).
  Medline CASGoogle Scholar
• 48 Ang C, Guiot MC, Ramanakumar AV, Roberge D, Kavan P. Clinical significance of molecular biomarkers in glioblastoma. Can. J. Neurol. Sci. 37, 625–630 (2010).
  Medline CASGoogle Scholar
• 49 Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64, 6892–6899 (2004).
  Medline CASGoogle Scholar
• 50 Tanase CP, Enciu AM, Mihai S, Neagu AI, Calenic B, Cruceru ML. Anti-cancer therapies in high grade gliomas. Curr. Proteomics 10, 246–260 (2013).
  Medline CASGoogle Scholar
• 51 Tannous BA, Kerami M, Van der Stoop PM et al. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. J. Natl Cancer Inst. 105, 1322–1331 (2013).
  Medline CASGoogle Scholar
• 52 Sievert AJ, Lang SS, Boucher KL et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc. Natl Acad. Sci. USA 110, 5957–5962 (2013).
  Medline CASGoogle Scholar
• 53 Nicolaides TP, Li H, Solomon D et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin. Cancer Res. 17, 7595–7604 (2011).
  Medline CASGoogle Scholar
• 54 Hummel R, Maurer J, Haier J. MicroRNAs in brain tumors : a new diagnostic and therapeutic perspective? Mol. Neurobiol. 44, 223–234 (2011).
  Medline CASGoogle Scholar
• 55 Towner RA, Jensen RL, Colman H et al. ELTD1, a potential new biomarker for gliomas. Neurosurgery 72, 77–90; discussion 91 (2013).
  MedlineGoogle Scholar
• 56 Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 95, 190–198 (2001).
  Medline CASGoogle Scholar
• 57 Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012–2024 (2005).
  Medline CASGoogle Scholar
• 58 Brown PD, Krishnan S, Sarkaria JN et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol. 26, 5603–5609 (2008).
  Medline CASGoogle Scholar
• 59 Raizer JJ, Abrey LE, Lassman AB et al. A Phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 12, 95–103 (2010).
  Medline CASGoogle Scholar
• 60 Neyns B, Sadones J, Joosens E et al. Stratified Phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann. Oncol. 20, 1596–1603 (2009).
  Medline CASGoogle Scholar
• 61 Thiessen B, Stewart C, Tsao M et al. A Phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother. Pharmacol. 65, 353–361 (2010).
  Medline CASGoogle Scholar
• 62 Takeuchi K, Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol. Pharm. Bull. 34, 1774–1780 (2011).
  Medline CASGoogle Scholar
• 63 Hegi ME, Rajakannu P, Weller M. Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr. Opin. Neurol. 25, 774–779 (2012).
  Medline CASGoogle Scholar
• 64 Gruber Filbin M, Dabral SK, Pazyra-Murphy MF et al. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat. Med. 19, 1518–1523 (2013).
  MedlineGoogle Scholar
• 65 Sami A, Karsy M. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. Tumour Biol. 34, 1991–2002 (2013).
  Medline CASGoogle Scholar
• 66 Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland EC. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 7, 356–368 (2005).
  Medline CASGoogle Scholar
• 67 Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5, 671–688 (2006).
  Medline CASGoogle Scholar
• 68 Thoreen CC, Kang SA, Chang JW et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023–8032 (2009).
  Medline CASGoogle Scholar
• 69 Poulikakos PI, Persaud Y, Janakiraman M et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387–390 (2011).
  Medline CASGoogle Scholar
• 70 Drappatz J, Lee EQ, Hammond S et al. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J. Neurooncol. 107, 133–138 (2012).
  Medline CASGoogle Scholar
• 71 Galanis E, Jaeckle KA, Maurer MJ et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J. Clin. Oncol. 27, 2052–2058 (2009).
  Medline CASGoogle Scholar
• 72 Friday BB, Anderson SK, Buckner J et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol. 14, 215–221 (2012).
  Medline CASGoogle Scholar
• 73 Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells’ VEGF production and angiogenesis. J. Neurosurg. 119, 1415–1423 (2013).
  MedlineGoogle Scholar
• 74 Barker CA, Bishop AJ, Chang M, Beal K, Chan TA. Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int. J. Radiat. Oncol. Biol. Phys. 86, 504–509 (2013).
  Medline CASGoogle Scholar
• 75 Bergen DC. Prophylactic antiepileptic drugs in patients with brain tumors. Epilepsy Curr. 5, 182–183 (2005).
  MedlineGoogle Scholar
• 76 Perry J, Zinman L, Chambers A, Spithoff K, Lloyd N, Laperriere N. The use of prophylactic anticonvulsants in patients with brain tumours-a systematic review. Curr. Oncol. 13, 222–229 (2006).
  Medline CASGoogle Scholar
• 77 Lee EQ, Puduvalli VK, Reid JM et al. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04–03. Clin. Cancer Res. 18, 6032–6039 (2012).
  Medline CASGoogle Scholar
• 78 Mizoguchi M, Guan Y, Yoshimoto K et al. Clinical implications of microRNAs in human glioblastoma. Front. Oncol. 3, 19 (2013).
  Medline CASGoogle Scholar
• 79 Presta LG, Chen H, O’Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
  Medline CASGoogle Scholar
• 80 Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740–745 (2009).
  Medline CASGoogle Scholar
• 81 Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145–147 (2004).
  Medline CASGoogle Scholar
• 82 Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56, 4032–4039 (1996).
  Medline CASGoogle Scholar
• 83 Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733–4740 (2009).
  Medline CASGoogle Scholar
• 84 Taal W, Oosterkamp HM, Walenkamp AME et al. A randomized Phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB study. J. Clin. Oncol. 31 (2013).
  Google Scholar
• 85 Clinicaltrials.gov: US National Library of Medicine 2013. http://clinicaltrials.gov/show/NCTM01290939
  Google Scholar
• 86 Gilbert MR, Dignam J, Won M et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J. Clin. Oncol. 31 (2013).
  Google Scholar
• 87 Chinot O, Wick W, Mason W et al. OT-03. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAglio. Neuro. Oncol. 14(Suppl.), Abstract OT-03 (2012).
  Google Scholar
• 88 Reardon DA, Herndon JE 2nd, Peters K et al. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J. Neurooncol. 107, 213–221 (2012).
  Medline CASGoogle Scholar
• 89 de Groot JF, Lamborn KR, Chang SM et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol. 29, 2689–2695 (2011).
  Medline CASGoogle Scholar
• 90 Seystahl K, Weller M. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? Expert Opin. Investig. Drugs. 21, 605–617 (2012).
  Medline CASGoogle Scholar
• 91 Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006).
  Medline CASGoogle Scholar
• 92 Zhang M, Kleber S, Rohrich M et al. Blockade of TGF-beta signaling by the TGFbetaR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res. 71, 7155–7167 (2011).
  Medline CASGoogle Scholar
• 93 Ferruzzi P, Mennillo F, De Rosa A et al. In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines. Int. J. Cancer 131, e33–e44 (2012).
  Medline CASGoogle Scholar
• 94 Bar EE, Chaudhry A, Lin A et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25, 2524–2533 (2007).
  Medline CASGoogle Scholar
• 95 Dunn GP, Fecci PE, Curry WT. Cancer immunoediting in malignant glioma. Neurosurgery 71, 201–222; discussion 222–203 (2012).
  MedlineGoogle Scholar
• 96 Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 4722–4729 (2010).
  MedlineGoogle Scholar
• 97 Clinicaltrials.gov. US National Library of Medicine. Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV) (2013) http://clinicaltrials.gov/ct2/show/NCT01480479
  Google Scholar
• 98 Parsa AT, Crane C, Han S et al. A Phase 2 multicenter trial of autologous heat shock protein-peptide vaccine (HSPPC-96) for recurrent glioblastoma multiforme (GBM) patients shows improved survival compared with a contemporary cohort controlled for age, KPS and extent of resection. AANS (2012).
  Google Scholar
• 99 Wheeler CJ, Black KL. DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin. Investig. Drugs. 18, 509–519 (2009).
  Medline CASGoogle Scholar
• 100 Clinicaltrials.gov. US National Library of Medicine. Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer. 2013. http://clinicaltrials.gov/show/NCTM01290939
  Google Scholar